INTRODUCTION {#sec0001}
============

In December 2019 in Wuhan (Hubei, China), a new coronavirus that had not been previously identified in humans was associated with a cluster of pneumonia cases.^1^ It rapidly propagated around various countries and on January 30, 2020, the WHO classified the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), coronavirus disease 2019 (COVID-19), as a Public Health Emergency of International Concern.^2^ On March 11, 2020, the WHO declared the state of pandemic.^3^ To date, the vast majority of countries worldwide have reported COVID-19 cases.^4^

Healthcare personnel (HCP) are at the forefront of the response to the COVID-19 pandemic, and as such, they are exposed to a higher infection risk.^5^ Up to 10% of the cases reported in China and Italy were among HCP.^6,7^ In Spain, 20,4% of the confirmed cases were among HCP.^8^

The protection of HCP is recognized as a critical priority to guarantee their health and the continuity of healthcare services.^9^ The occupational exposure of this population must be addressed widely. One of the strategies for disease control and prevention in healthcare institutions is the surveillance and management of exposed personnel.^10,11^ Two fundamental approaches form part of this strategy: (1) continuous monitoring and individual risk assessment of all HCP exposed to COVID-19 and (2) identification of HCP that develop symptoms consistent with the disease. These strategies enable the establishment of appropriate diagnostic testing and isolation measures in the workplace to stop the spread of the disease.

There is limited information on the risk of infection by SARS-CoV-2 among HCP, and the available data come from limited case series that target specific aspects of this population.^12--18^ No studies have been reported that analyze the risk of HCP in diverse environments (healthcare assistance and social interactions). Improving the surveillance and understanding of how HCP exposure to SARS-CoV-2 translates to a risk of infection is essential to establish the most effective disease control and prevention recommendations among HCP.^19^

The aim of this study is to uncover the frequency, associated factors, and characteristics of COVID-19 and severe COVID-19 in HCP at Alicante\'s Healthcare Department (HCD) in Spain.

METHODS {#sec0002}
=======

Study Sample {#sec0003}
------------

An observational study was carried out in a HCD comprised by a tertiary hospital, 12 primary healthcare centers, and a total of 3,900 HCP. It spanned 7 epidemiological weeks, from Week 10 (starting March 2, 2020) up until Week 16 (ending April 19, 2020). During this period, it was compulsory for all HCP to inform the Preventive Medicine Service if they showed any compatible COVID-19 symptoms or if they had had contact with a confirmed or suspected COVID-19 case patient.

Measures {#sec0004}
--------

The HCP were evaluated under the two assistance programs deployed by the Preventive Medicine Service. The first was the Biological Risk HCP Evaluation Program, in which HCP were tested when they showed any severity of compatible SARS-CoV-2 infection symptoms: mild fever (≥37°Celsius) or fever (≥38°Celsius), cough, nasal congestion, anosmia, rhinorrhea, sore throat, dysgeusia, headache, asthenia, or dyspnea. The second was the HCP Contact Tracing Program, through which all HCP who were exposed to a suspected or confirmed COVID-19 case patient in any environment (workplace, family, or social) were evaluated. As part of this second program, they were subjected to a contact tracing study during the 14 days following the exposure in order to identify all of the potential contacts that had shown symptoms. Both programs were stablished before the beginning of the pandemic, and the HCD personnel were already familiar with the procedures.

A contact of an HCP with a confirmed COVID-19 case patient was defined as someone being in the same place in which a confirmed case patient was showing symptoms. All HCP with symptoms compatible with COVID-19 had a SARS-CoV-2 respiratory tract sample test via polymerase chain reaction (PCR). HCP were considered as a confirmed COVID-19 case patient when they showed symptoms and had two positive microbiological PCR tests for SARS-CoV-2 (a first PCR screening test that when rendered positive was confirmed with a second PCR test).^20^ HCP were considered to have severe COVID-19 when they required hospitalization.

Among all evaluated HCP, the following data were collected: age, sex, professional category (physician, nurse, nursing assistant or others not performing strict clinical care like hospital wardens, administrative assistants, or physiotherapists), and the service in which they were working. Regarding the exposure risk, the reason, type, and characteristics of the contact were registered. The contact reason was classified based on the exposure 14 days prior to initiation of symptoms: (1) healthcare-associated, when the contact occurred when providing clinical care to a patient with confirmed COVID-19; (2) workplace social interactions among HCP, when the contact occurred with another HCP with confirmed COVID-19 via interactions, work meetings, or breaks; and (3) other social interactions, when the HCP had contact with a positive COVID-19 case patient in the community outside the work environment. The type of contact was classified as: (1) close, when the evaluated HCP was at a distance of \<2 meters for ≥15 minutes with a case patient who showed symptoms; (2) occasional, when the HCP was in the same place and the conditions did not comply with the above; and (3) unknown, when the potential infection source was unidentified. For healthcare-associated contacts, the protection level was classified as: (1) Protected, when the appropriate extended droplet precautions were followed (use of a surgical mask or a N95, FFP2, or FFP3 respirator) and additional eye protection was used depending on the risk of the maneuver (aerosol-generating procedures were considered high risk),^10^ and (2) not protected, when the extended droplet precautions were not followed. For those contacts related to social environments (workplace and community), the protection level was classified as: (1) protected, when the HCP used a surgical mask during the contact, and (2) not protected, when a mask was not used during the contact. When more than one type of contact occurred, it was assigned to the least protected exposure. When a social contact could not be clearly established, the type of contact was considered healthcare-associated.

The HCP with confirmed COVID-19 were interviewed using the Epidemiological Survey of the Regional Public Health Department Compulsory Disease Declaration. In this survey, the following data were included: presence of symptoms, clinical comorbidities, influenza vaccination status, and hospital admission requirement or intensive care unit (ICU) requirement, among others.

Statistical Analysis {#sec0005}
--------------------

The evolution over time and the characteristics of all evaluated HCP were described, both symptomatic with confirmed COVID-19 and those that required hospitalization (severe COVID-19 cases). The absolute and relative frequencies shown as percentages were calculated for each variable. Prevalence and 95% CIs were calculated for the following groups: evaluated HCP, HCP with symptoms, HCP with COVID-19, HCP with severe COVID-19, and HCP who required admission to the ICU. To evaluate the association between the different variables and the main outcome (confirmed COVID-19), chi-square tests were performed. To quantify the effect of the association, ORs and 95% CIs were calculated. AORs and 95% CIs were calculated using a logistic regression model. This model was based on the variables that showed an association in the bivariate analysis. Statistical significance was set at *p*\<0.05 for all hypothesis determinations. Analysis was conducted using SPSS, version 25.0.

RESULTS {#sec0006}
=======

Between March 2 and April 19, 2020, a total 45.9% (1,791/3,900) of the HCP in the HCD were evaluated either because they showed symptoms or because they were part of a contact tracing study. The remaining 54.1% (2,109/3,900) did not show any symptoms and were not part of any contact tracing studies ([Figure 1](#fig0001){ref-type="fig"} ). Of the 1,791 evaluated HCP, 32.5% (582/1,791) presented with symptoms, and 67.5% (1,209/1,791) were identified through a contact tracing investigation. Of the latter, 16.7% (202/1,209) showed symptoms within the 14 days after they were exposed to a suspected or confirmed COVID-19 case patient. All of the HCP personnel who showed symptoms at any point in time (*n*=784) had a PCR test performed. Of these, 19.9% (156/784) were confirmed to have COVID-19. Of these HCP with confirmed COVID-19, 11.5% (18/156) required hospital admission. Of these, 16.7% (3/18) required admission to the ICU.Figure 1Healthcare personnel characteristics and type of study in which it was evaluated.Figure 1

The daily distribution of new cases in evaluated HCP, both symptomatic and those that required hospital admission, is shown in Appendix Figure 1. A significant increase in the number of evaluated HCP from both populations was observed between March 11 and March 12, 2020. This was followed by a plateau and a steady decrease of new cases from March 25, 2020. Characteristics of HCP are shown in [Table 1](#tbl0001){ref-type="table"} .Table 1Distribution of the Healthcare Personnel EvaluatedTable 1CharacteristicsEvaluated (n=1,791)Symptomatic (n=784)Confirmed (n=156)Severe confirmed (n=18)% (n)% (n)% (n)% (n)Age, years \<6085.1 (1,525)88.1 (691)86.5 (135)72.2 (13) ≥6014.9 (266)11.9 (93)13.5 (21)27.8 (5)Sex Male24.8 (444)21.6 (169)24.4 (38)55.6 (10) Female75.2 (1,347)78.4 (615)75.6 (118)44.4 (8)Professional category Physician22.7 (407)27.2 (213)38.5 (60)50.0 (9) Nurse36.6 (655)34.4 (270)31.4 (49)16.7 (3) Nursing assistant/Technicians20.3 (363)23.6 (185)17.3 (27)16.7 (3) Other[a](#tb1fn1){ref-type="table-fn"}20.4 (366)14.8 (116)12.8 (20)16.7 (3)Contact reason Healthcare-associated29.6 (531)26.7 (209)17.9 (28)27.8 (5) Workplace social interactions60.6 (1,085)53.3 (418)53.8 (84)50.0 (9) Other social interactions9.8 (175)20.0 (157)28.2 (44)22.2 (4)Contact type Close47.7 (854)66.7 (523)76.3 (119)72.2 (13) Occasional42.9 (769)23.2 (182)17.3 (27)22.2 (4) Unknown9.4 (168)10.1 (79)6.4 (10)5.6 (1)Department Emergency service5.1 (91)4.7 (37)3.8 (6)11.1 (2) Pediatric areas[b](#tb1fn2){ref-type="table-fn"}6.5 (45)6.1 (48)2.6 (4)0.0 (0) Critical care units[c](#tb1fn3){ref-type="table-fn"}15.2 (24)15.3 (120)19.2 (30)22.2 (4) Medical wards - adults35.5 (635)35.8 (281)26.9 (42)16.7 (3) Primary health care12.6 (226)12.4 (97)14.7 (23)16.7 (3) Non COVID-19 wards[d](#tb1fn4){ref-type="table-fn"}25.1 (450)25.6 (201)32.7 (51)33.3 (6)[^1][^2][^3][^4]

The prevalence of symptomatic HCP was 20.1% (95% CI=18.8%, 21.4%). The prevalence of symptomatic confirmed COVID-19 was 4.0% (95% CI=3.4%, 4.6%). Severe COVID-19 cases accounted for 0.5% (95% CI=0.2%, 0.7%) and 0.1% (0.0%, 0.2%) ultimately requiring admission to the ICU (Appendix Table 1).

Among symptomatic HCP, the only significant and independent variable associated with the development of confirmed COVID-19 was the type of contact (protected or not protected). The frequency of confirmed COVID-19 HCP case patients with symptoms who had a non-protected exposure was 22.8% (112/491) and 13.7% (40/293) when its exposure was protected (AOR=2.2, 95% CI=1.2, 3.9) ([Table 2](#tbl0002){ref-type="table"} ).Table 2Risk Factors for Disease Development Among Healthcare Personnel With Symptoms That Were Subject to a PCR Test (n=784)Table 2CharacteristicsCOVID-19 case frequency% (n)OR (95% CI)*p*-valueAOR (95% CI)*p*-valueAge, years \<6019.5 (135/691)10.490‒‒ ≥6022.6 (21/93)1.2\
(0.7, 2.0)Sex Male22.5 (38/169)1.2\
(0.8, 1.8)0.341‒‒ Female19.2 (118/615)1Professional category Physician28.2 (60/213)1.9\
(1.1, 3.3)0.0291.5\
(0.7, 3.1)0.262 Nurse18.1 (49/270)1.1\
(0.6, 1.9)0.8311.3\
(0.6, 2.7)0.459 Nurse assistant/Technician14.6 (27/185)0.8\
(0.4, 1.5)0.5390.6\
(0.3, 1.2)0.154 Other[a](#tb2fn1){ref-type="table-fn"}17.2 (20/116)11Contact reason Healthcare-associated13.4 (28/209)11 Workplace social interactions20.1 (84/418)1.6\
(1.0, 2.6)0.0400.6\
(0.3, 1.1)0.125 Other social interactions28.0 (44/157)2.5\
(1.5, 4.3)0.0011.5\
(0.8, 3.0)0.241Contact type Close22.8 (119/523)2.0\
(1.0, 4.1)0.0452.1\
(0.8, 5.1)0.105 Occasional14.8 (27/182)1.2\
(0.6, 2.6)0.6441.4\
(0.5, 3.9)0.479 Unknown12.7 (10/79)11Contact characteristics Not protected22.8 (112/491)1.9\
(1.3, 2.7)0.0012.2\
(1.2, 3.9)0.009 Protected13.7 (40/293)11Department Emergency service16.2 (6/37)0.6\
(0.2, 1.4)0.2350.7\
(0.2, 1.9)0.442 Pediatric areas[b](#tb2fn2){ref-type="table-fn"}8.3 (4/48)0.3\
(0.1, 0.8)0.0160.4\
(0.1, 2.2)0.112 Critical care units[c](#tb2fn3){ref-type="table-fn"}25.0 (30/120)1.0\
(0.6, 1.7)0.9410.8\
(0.3, 1.7)0.296 Adults medical wards14.9 (42/281)0.5\
(0.3, 0.8)0.0050.7\
(0.4, 1.4)0.370 Primary health care23.7 (23/97)0.9\
(0.5, 1.6)0.7561.1\
(0.5, 2.2)0.888 Non COVID-19 wards[d](#tb2fn4){ref-type="table-fn"}25.4 (51/201)11[^5][^6][^7][^8][^9]

Among the HCP who required hospital admission (severe COVID-19 cases), the variables that were significantly associated with this outcome were sex and the presence of pneumonia. Hospital admission was required for 26.3% (10/38) of male HCP with COVID-19 compared with 6.8% (8/118) of female HCP (OR=4.9, 95% CI=1.8, 13.6). Hospital admission was required for 64.3% (9/14) of HCP with COVID-19 who were diagnosed with pneumonia, compared with 6.3% (9/142) of HCP with COVID-19 who were not diagnosed with pneumonia (OR=26.6, 95% CI=7.4, 96.1) ([Table 3](#tbl0003){ref-type="table"} ).Table 3Prognostic Factors for the Development of Severe COVID-19 Among Healthcare Personnel (n=156)Table 3CharacteristicsSevere COVID19 Case Frequency% (n)OR (95%CI)*p*-valueAge, years \<609.6 (13/135)10.071 ≥6023.8 (5/21)2.9 (0.9, 9.3)Sex Male26.3 (10/38)4.9 (1.8, 13.6)**0.002** Female6.8 (8/118)1Pre-existing conditions Shows a pre-existing condition (yes)12.5 (6/48)1.1 (0.4, 3.2)0.802 Diabetes (yes)0.0 (0/2)N/A‒ Chronic hepatic disease (yes)0.0 (0/1)N/A‒ Chronic kidney disease (yes)100.0 (2/2)N/A‒ Immunodeficiency (yes)100.0 (1/1)N/A‒ Cardiovascular disease (yes)22.2 (2/9)2.3 (0.4, 12.1)0.278 Chronic lung disease (yes)0.0 (0/7)N/A‒ Chronic neurological disease (yes)0.0 (0/1)N/A‒ Pregnancy (yes)0.0 (0/1)N/A‒ Cancer (yes)0.0 (0/2)N/A‒ Arterial hypertension (yes)27.3 (3/111)3.2 (0.7, 13.5)0.118 Other pre-existing conditions (yes)6.3 (2/32)0.4 (0.1, 2.0)0.370Influenza vaccination Yes11.9 (8/67)1.1 (0.4, 2.9)0.892 No11.2 (10/89)1Clinical characteristics Fever (yes)13.2 (14/106)1.8 (0.6, 5.6)0.428 Cough (yes)10.7 (13/121)0.7 (0.2, 2.2)0.564 Pneumonia (yes)64.3 (9/14)26.6 (7.4, 96.1)**\<0.001** Headache (yes)9.7 (6/62)0.7 (0.3, 2.1)0.555 Shivers (yes)17.0 (9/53)2.1 (0.8, 5.8)0.127 Coryza (yes)14.3 (3/21)1.3 (0.4, 5.1)0.713 Myalgia (yes)12.5 (11/88)1.2 (0.5, 3.4)0.669 Vomits (yes)30.0 (3/10)3.7 (0.9, 16.0)0.093 Diarrhea (yes)15.4 (6/39)1.6 (0.6, 4.6)0.393 ARDS (yes)100.0 (2/2)N/A‒ Acute kidney failure (yes)100.0 (1/1)9.1 (5.8, 14.3)0.115 Ageusia (yes)14.3 (5/35)1.4 (0.4, 4.2)0.556 Anosmia (yes)13.5 (5/37)1.3 (0.4, 3.8)0.768 Ocular symptoms (yes)20.0 (1/5)2.0 (0.2, 18.7)0.463 Migraine (yes)8.0 (6/75)0.5 (0.2, 1.4)0.183 Other (yes)8.7 (10/115)0.4 (0.2, 1.1)0.086[^10][^11]

DISCUSSION {#sec0007}
==========

The data presented here do not only show the frequency of HCP with COVID-19, but also the risk factors, prognosis, the evolution of HCP COVID-19 cases over time. This work represents a comprehensive study on almost half of the HCP of an HCD constituted by a tertiary general hospital and its 12 primary care centers.

In this study, the prevalence of COVID-19 among HCP was 4.0% (95% CI=3.4%, 4.6%). The first sets of international data showed that up to 10% of the COVID-19 cases in China and Italy were among HCP.^6,7^ More recent data from the U.S. between February 12 and April 9, 2020 showed that only in 16% of the reported cases a variable was available to record if the patient was a HCP. Of these, 19% were identified as HCP.^12^ In England, between March 10 and 31, 2020, a total of 1,666 SARS-CoV-2 tests were performed among 1,654 HCP.^21^ SARS-CoV-2 was detected in 240 (14%) of these tests. In a Spain-wide study, 20.4% of the cases through April 23, 2020 were reported as HCP.^8^ According to preliminary results from a hospital in Madrid, through March 3, 2020, HCP comprised 11.6% of their cases.^13^

Taking into account these data on the prevalence of COVID-19 among HCP, the rate of COVID-19 cases in this department is considered lower than what has been published to date. This statement requires further clarification as the different studies cannot be directly compared owing to the discordant methodologies used. This study did not test asymptomatic HCP, even though the existence of asymptomatic COVID-19 cases has been decribed.^22^ According to the published data, the proportion of asymptomatic cases would be in the range of 17.9%^23^ to 32%.^24^ Taking this into account, the prevalence in this department would increase to 4.7%--5.3%.

A critical point would be to determine if the prevalence of COVID-19 among HCP is higher than that of the general population. This would assess the potential additional risk to which HCP are exposed and would allow understanding of whether the measures of the programs for disease control and prevention are effective. Unfortunately, this direct comparison is not possible as the true percentage of the population affected by COVID-19 in Spain is not known. Following a model developed by Imperial College London, the proportion of the infected population in Spain as of March 28, 2020 was 15.0% (95% CI=3.7%, 41.0%).^25^ Although these estimations can aid understanding of the impact of COVID-19 in the general population, to establish comparisons with HCP, it would be necessary to obtain prevalence data of COVID-19 in the population based on determination of immunoglobulin G after the epidemic stage of the disease.

In this study, the only variable that was significantly and independently associated with the development of COVID-19 was having had a non-protected contact (AOR=2.2, 95% CI=1.2, 3.9). Some of these non-protected contacts took place while providing clinical care to patients who had not originally been suspected to have COVID-19; in these cases, appropriate precautionary measures were not taken. Non-protected contacts also took place during social interactions in the workplace or in the community where a surgical mask was not used. The age, sex, professional category, contact reason, and the contact type were not independently associated with the development of COVID-19. The previous statement also applies to the different services in which the HCP could potentially be more exposed, like the emergency service or critical care units, in line with what was determined in other case series.^13^ In fact, the services with the highest proportion of symptomatic HCP with confirmed COVID-19 were the non-COVID-19 wards. This is in line with the HCP screening study carried out in England,^21^ which is in favor of the effectiveness of the isolation protocols and personal protective equipment. As long as the exposure is protected, independently of the contact carried out, the infection risk diminishes. This statement is supported by a study in California in which among the 121 HCP with a non-protected exposure to a not-yet-diagnosed COVID-19 patient, 3 resulted positive for SARS-CoV-2, in comparison to the 146 HCP who had a protected exposure using the appropriate PPE of whom none tested positive for SARS-CoV-2.^18^ In addition, a Chinese study reported a high COVID-19 transmission rate among HCP, but when the appropriate PPE measures were implemented, the transmission among HCP drastically reduced.^6^ Hence, the use of the appropriate PPE by all HCP is the key to their protection, and as such it should be taken into account when directing resources to guarantee their availability. However, it is thought provoking that in this series, 82.1% (128/156) of the HCP COVID-19 cases were associated with social interactions in the work environment with other colleagues or outside of work with friends or family, in contrast to the 17.9% (28/156) of cases that were strictly associated to direct clinical care.

If the goal is to reduce the infection risk among HCP, the disease control and prevention strategies should not just be targeted to direct clinical care but also the rest of the situations occurring in the healthcare and community settings. This is the reason behind the decision to require the universal use of a surgical mask among HCP. This applied when they were within 1 meter of other colleagues or patients (in the work environment), but also of other friends and relatives (in the social and family environments). The evaluation of the effectivity of this strategy was evaluated in a separate study.^26^

Regarding the HCP characteristics, the number of evaluated female HCP was clearly higher than the number of male HCP, in line with the sex distribution among the department HCP, were the proportion of female HCP is also higher. The prevalence of COVID-19 among male and female HCP was not different, but being male was associated with the development of a more severe form of disease (OR=4.9, 95% CI=1.8, 13.6). This was also shown in a preliminary study on the influence of sex in the morbidity and mortality of COVID-19, which determined that male case patients tended to be more severe than those in female patients (*p*=0.035); the mortality (not studied in this manuscript) was also higher in male than female case patients (70.3% vs 29.7%, *p*=0.016).^27^ The second factor associated with admission was the presence of pneumonia. These data are relevant as an early identification of the risk factors associated with the severity of the disease can facilitate a prompt therapeutic response for the patient in case it is necessary. However, as the date of onset of symptoms was not available, it was not possible to identify which early symptoms help predict severe disease.

Because data collection was not focused on studying the severity of the disease, to perform a more in-depth analysis of the associated COVID-19 prognostic factors among HCP, it would be necessary to gather more refined clinical data.

Limitations {#sec0008}
-----------

There are various limitations to this study. First, there was potential selection bias due to the HCP who were not evaluated (54.1%) either because they did not present with symptoms or because when they were contacted as part of a contact tracing studies, they were not symptomatic (a PCR test was not indicated). This could potentially have led to underdiagnosis of COVID-19 among HCP. Second, this study was observational in nature. Third, classification bias that may have arisen when an infection in an HCP was attributed to a specific contact when multiple contacts had taken place. Even when there is a clear hypothesis for the infection source, this cannot always be proven. Fourth, the presence of comorbidities (pre-existing conditions) was obtained through telephone interviews as part of epidemiological surveys.

CONCLUSIONS {#sec0009}
===========

A surveillance and monitoring program centered around HCP allows for ascertainment of the COVID-19 risk factors in this population, and can thus reshape the disease prevention and control strategies to improve HCP protection.
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Image, application 1

Supplemental materials associated with this article can be found in the online version at <https://doi.org/10.1016/j.amepre.2020.07.014>.

[^1]: Hospital wardens, administrative assistants, physiotherapist, etc.

[^2]: Pediatric emergency service, surgical pediatric wards, medical pediatric wards and pediatric intensive care unit.

[^3]: Medical intensive care unit, surgical intensive care unit and operating theatre.

[^4]: Non COVID-19 wards: surgical wards adults; administrative areas; central services: laboratory, microbiology, pharmacy, radiology, blood bank, etc.

[^5]: *Notes*: AOR based on professional category, reason for contact, type of contact, contact characteristics and department.

[^6]: Hospital wardens, administrative assistants, physiotherapist, etc.

[^7]: Pediatric emergency service, surgical pediatric wards, medical pediatric wards and pediatric intensive care unit.

[^8]: Medical intensive care unit, surgical intensive care unit and operating theatre.

[^9]: Non COVID-19 wards: adults surgical wards; administrative areas; central services: laboratory, microbiology, pharmacy, radiology, blood bank, etc.

[^10]: *Note*: Boldface indicates statistical significance (*p*\<0.05).

[^11]: ARDS, acute respiratory distress syndrome.
